Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy

Olivier, A.; Petyt, G.; Cortot, A.; Scherpereel, Arnaud; Hossein-Foucher, Claude

doi:10.1097/mnm.0000000000000145

Cited by 15 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to SUV max , TLG incorporates the metabolic burden and disease extent and may provide a higher predictive value. The results of our study revealed that whole-body tumor glycolysis represented by TLG WBR was a strong predictor of survival, which was similar to previously reported findings [ 18 , 23 – 24 ]. However, our study indicated that total glycolysis in the primary tumor alone (TLG T ) was not an independent predictor of survival, in line with some recent studies [ 19 , 30 ].…”

Section: Discussionsupporting

confidence: 92%

“…Regarding the correlation between the PET/CT metabolic parameters (SUV max , primary TLG, and whole-body TLG) and survival in patients with advanced NSCLC, there has been some disagreement among researchers. Some studies have reported that whole-body TLG is a better prognostic predictor of worse OS and PFS in patients with advanced NSCLC [ 23 – 24 ], whereas other studies have found no such correlation [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status

et al. 2016

View full text Add to dashboard Cite

The study objective was to retrospectively analyze the metabolic variables derived from 18 F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) as predictors of progression-free survival (PFS) and overall survival (OS) in advanced lung adenocarcinoma stratified by epidermal growth factor receptor (EGFR) mutation status. A total of 176 patients (91, EGFR mutation; 85, wild-type EGFR) who underwent 18F-FDG PET/CT before treatment were enrolled. The main 18F-FDG PET/CT-derived variables: primary tumor maximum standardized uptake value (SUVmaxT), primary tumor total lesion glycolysis (TLGT), the maximum SUVmax of all selected lesions in whole body determined using the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria (SUVmaxWBR), and whole-body total TLG determined using the RECIST 1.1 criteria (TLGWBR) were measured. Survival analysis regarding TLGWBR, and other factors in advanced lung adenocarcinoma patients stratified using EGFR mutation status, were evaluated. The results indicated that high TLGWBR (≥259.85), EGFR wild-type, and high serum LDH were independent predictors of worse PFS and OS in all patients with advanced lung adenocarcinoma. Among patients with wild-type EGFR, only TLGWBR retained significance as an independent predictor of both PFS and OS. Among patients with the EGFR mutation, high serum LDH level was an independent predictor of worse PFS and OS, and high TLGWBR (≥259.85) was an independent predictor of worse PFS but not worse OS. In conclusion, TLGWBR is a promising parameter for prognostic stratification of patients with advanced lung adenocarcinoma and EGFR status; however, it cannot be used to further stratify the risk of worse OS for patients with the EGFR mutation. Further prospective studies are needed to validate our findings.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status

et al. 2016

View full text Add to dashboard Cite

show abstract

“…8,9 However, it should be noted that the prognostic significance of TLG RECIST found in our study was limited to patients without EGFR mutations. The low frequency of EGFR mutations in whites 5 may explain the comparable findings.…”

Section: Discussionmentioning

confidence: 62%

Total Lesion Glycolysis Determined per RECIST 1.1 Criteria Predicts Survival in EGFR Mutation-Negative Patients With Advanced Lung Adenocarcinoma

Chou

Yang

et al. 2015

Clinical Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…For quantitation, we assessed [ 18 F]FHBG total activity within the generated ROI (SUV mean × volume of interest) as an unbiased measure of [ 18 F]FHBG signal in a fixed volume region within the brain (namely the tumor) and in the setting where the [ 18 F]FHBG signal, and therefore CTLs, was widely dispersed after CTL infusions. This metric is comparable to total lesion glycolysis used with [ 18 F]2-fluoro-2-deoxy-D-glucose ([ 18 F]FDG) PET, which is a more sensitive marker than SUV max or SUV mean for the evaluation of therapeutic response and prognosis (44–46). …”

Section: Discussionmentioning

confidence: 97%

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma

et al. 2017

View full text Add to dashboard Cite

High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy using CD8+ cytotoxic T lymphocytes (CTLs), engineered to express both herpes simplex virus type-1 thymidine kinase (HSV1-TK) and interleukin (IL)-13 zetakine chimeric antigen receptor (CAR), is a treatment strategy with considerable potential. To optimize this and related immunotherapies, it may be helpful to monitor CTL viability and trafficking to glioma cells. We show that noninvasive positron emission tomography (PET) imaging with 9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]guanine ([18F]FHBG) can track HSV1-tk reporter gene expression present in CAR-engineered CTLs. [18F]FHBG imaging was safe and enabled the longitudinal imaging of T cells stably transfected with a PET reporter gene in patients. Further optimization of this imaging approach for monitoring in vivo cell trafficking should greatly benefit various cell-based therapies for cancer.

show abstract

Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy

Abstract: MV and TLG are powerful prognostic factors in advanced-stage lung adenocarcinoma being treated with chemotherapy. Focusing on the intrathoracic primary tumour increases the prognostic value of PET in these patients.

Cited by 15 publications

References 9 publications

Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status

Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status

Total Lesion Glycolysis Determined per RECIST 1.1 Criteria Predicts Survival in EGFR Mutation-Negative Patients With Advanced Lung Adenocarcinoma

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma

Contact Info

Product

Resources

About